Abliva AB (NEVPF)
0.01
0.00 (0.00%)
USD |
OTCM |
Apr 25, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 10.56M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -- |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 1.504 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.34% |
Profile
| Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase. |
| URL | https://www.abliva.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 23, 2024 |
| Last Earnings Release | Feb. 23, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase. |
| URL | https://www.abliva.com |
| Investor Relations URL | N/A |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 23, 2024 |
| Last Earnings Release | Feb. 23, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |